- Investing Ideas
- French Pharmaceuticals & Biotech Top Stock Picks from Analysts
French Pharmaceuticals & Biotech Top Stock Picks from Analysts
Results
17
Companies which are more than 50% undervalued based on analyst price target.
17 companies
Nanobiotix
Market Cap: €1.7b
Operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
NANO
€33.48
7D
-1.8%
1Y
628.6%
Inventiva
Market Cap: €903.8m
A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.
IVA
€3.83
7D
2.5%
1Y
37.6%
Valneva
Market Cap: €414.9m
A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
VLA
€2.19
7D
-4.3%
1Y
-20.5%
Transgene
Market Cap: €200.2m
A biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France.
TNG
€0.73
7D
-1.7%
1Y
-6.5%
Cellectis
Market Cap: €171.8m
A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
ALCLS
€2.37
7D
-12.4%
1Y
49.6%
Innate Pharma
Market Cap: €146.4m
Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
IPH
€1.56
7D
-2.0%
1Y
-1.3%
Sensorion
Market Cap: €138.5m
A biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France.
ALSEN
€0.27
7D
4.3%
1Y
-18.5%
OSE Immunotherapeutics
Market Cap: €76.5m
A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.
OSE
€3.25
7D
-4.5%
1Y
-38.2%
Adocia
Market Cap: €76.0m
A clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity.
ADOC
€3.88
7D
-1.2%
1Y
-14.1%
ABIONYX Pharma
Market Cap: €65.7m
A biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States.
ABNX
€1.86
7D
-4.0%
1Y
51.9%
THX Pharma Société Anonyme
Market Cap: €52.0m
A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.
ALTHX
€3.77
7D
5.6%
1Y
250.7%
MaaT Pharma
Market Cap: €51.9m
A late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.
MAAT
€2.76
7D
2.0%
1Y
-37.8%
AB Science
Market Cap: €49.4m
A clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France.
AB
€0.62
7D
-17.6%
1Y
-49.8%
Nicox
Market Cap: €33.3m
Operates as an ophthalmology company in France and internationally.
ALCOX
€0.38
7D
-2.2%
1Y
25.2%
Advicenne
Market Cap: €23.6m
A specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally.
ALDVI
€1.62
7D
1.1%
1Y
19.8%
GenSight Biologics
Market Cap: €18.9m
A clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.
SIGHT
€0.081
7D
-2.3%
1Y
-36.1%
Valbiotis
Market Cap: €18.7m
Engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia.
ALVAL
€0.79
7D
1.5%
1Y
-12.3%